Sustained Weight Loss After Treatment With a Glucagon-Like Peptide-1 Receptor Agonist in an Obese Patient With Schizophrenia and Type 2 Diabetes

Dr. Knop has received lecture, consulting, or advisory board membership fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly Danmark A/S, Gilead Sciences, Merck Sharp and Dohme, Novo Nordisk, Ono Pharmaceuticals, Sanofi, and Zealand Pharma. Dr. Vilsbøll has received consulting, lecture, or advisory board fees from AstraZeneca, Bohringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Merck Sharp and Dohme, Novartis, Novo Nordisk, Sanofi Aventis, and Zealand Pharma. Dr. Ebdrup has received lecture or advisory board fees from Bristol-Myers Squibb and Eli Lilly Danmark A/S. Drs. Ishøy and Glenthøj report no financial relationships with commercial interests.